Clinical Trial Update: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating BHV-7000 for idiopathic generalized epilepsy with generalized tonic-clonic seizures has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

Drugs mentioned

• BHV-7000

Snippet

Sponsor: Biohaven Therapeutics Ltd. | Conditions: Generalized Epilepsy | Phase 2, Phase 3 | Status: TERMINATED